0000000000925686

AUTHOR

Chahéra Khouatra

showing 2 related works from this author

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

2018

International audience; Objective - To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. Methods - The 28-month Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis trial compared rituximab with azathioprine to maintain remission in patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis or renal-limited ANCA-associated vasculitis. Thereafter, prospective patient follow-up lasted until month 60. The primary endpoint was the major-relapse rate at month 60. Relapse and serious adverse event-free …

MaleAzathioprineKaplan-Meier Estimateurologic and male genital diseasesGastroenterologySeverity of Illness Index0302 clinical medicineimmune system diseasesRecurrenceRisk FactorsAzathioprineClinical endpointImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasestreatmentRemission InductionMiddle Aged3. Good healthTreatment OutcomeAntirheumatic AgentsRituximabFemalesystemic vasculitisGranulomatosis with polyangiitisMicroscopic polyangiitisVasculitisRituximabImmunosuppressive Agentsmedicine.drugSystemic vasculitisAdultmedicine.medical_specialtyImmunologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGeneral Biochemistry Genetics and Molecular BiologyDrug Administration ScheduleAntibodies Antineutrophil Cytoplasmic03 medical and health sciencesRheumatologyInternal medicinemedicineHumanscardiovascular diseasesLymphocyte CountGlucocorticoidsAnti-neutrophil cytoplasmic antibodyAged030203 arthritis & rheumatology[SDV.GEN]Life Sciences [q-bio]/Geneticsgranulomatosis with polyangiitisDose-Response Relationship Drugbusiness.industrymedicine.diseaserespiratory tract diseases[ SDV.GEN ] Life Sciences [q-bio]/GeneticsbusinessAnnals of the rheumatic diseases
researchProduct

Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

2016

The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail.In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease.The study population included 157 patients (mean±sd age 49.4±14.1 years), with a mean±sd blood eosinophil count of 7.4±6.4×109 L−1 at diagnosis. There was a mean±sd of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corti…

MalePediatricsAdministration OralDiseaseChurg-Strauss SyndromeBronchoalveolar LavageSeverity of Illness Index0302 clinical medicineAdrenal Cortex HormonesEosinophilicEosinophiliaAged 80 and overNomenclatureSystemic VasculitisCohortMiddle AgedTerm-follow-upPrognosis3. Good healthRespiratory Function TestsManagementTreatment OutcomeCohortAntineutrophil cytoplasmic antibodiesPopulation studyFemaleFrancemedicine.symptomGranulomatosis with polyangiitisConsensus conferencePulmonary and Respiratory MedicineAdultmedicine.medical_specialtyAdolescentVasculitides[ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology environment/HealthGranulomatosis03 medical and health sciencesYoung AdultEosinophiliamedicineHumansAnti-neutrophil cytoplasmic antibodyAsthmaAgedRetrospective Studies030203 arthritis & rheumatology[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/Healthbusiness.industryGranulomatosis with Polyangiitisasthmamedicine.diseaseEosinophils030228 respiratory systemImmunologybusinessTomography X-Ray Computed
researchProduct